Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Subscribe To Our Newsletter & Stay Updated